Literature DB >> 27172124

Oxybutynin for the Treatment of Primary Hyperhidrosis: Current State of the Art.

Anna Campanati1, Stamatis Gregoriou2, George Kontochristopoulos3, Annamaria Offidani1.   

Abstract

Oxybutynin is an anticholinergic drug with an emerging role in the treatment of hyperhidrosis. Several recent studies have documented that it is effective both in focal and generalized hyperhidrosis and shows universally good response among different groups of patients regardless of age, gender, and weight. The most common adverse event is dry mouth reported by almost all patients treated. The way this might affect long-term compliance and tolerability should be better investigated in the future.

Entities:  

Keywords:  Botulinum toxin; Children; Hyperhidrosis; Sweat glands; Xerostomia

Year:  2015        PMID: 27172124      PMCID: PMC4857824          DOI: 10.1159/000371581

Source DB:  PubMed          Journal:  Skin Appendage Disord        ISSN: 2296-9160


  38 in total

1.  Impairment in quality of life among patients seeking surgery for hyperhidrosis (excessive sweating): preliminary results.

Authors:  M Amir; A Arish; Y Weinstein; M Pfeffer; Y Levy
Journal:  Isr J Psychiatry Relat Sci       Date:  2000       Impact factor: 0.481

Review 2.  Topical pharmacological treatment.

Authors:  Erhard Hölzle
Journal:  Curr Probl Dermatol       Date:  2002

3.  Evaluation of quality of life over time among 453 patients with hyperhidrosis submitted to endoscopic thoracic sympathectomy.

Authors:  Nelson Wolosker; José Ribas Milanes de Campos; Paulo Kauffman; Laert Andrade de Oliveira; Marco Antonio Soares Munia; Fábio Biscegli Jatene
Journal:  J Vasc Surg       Date:  2011-11-01       Impact factor: 4.268

4.  Treatment of primary hyperhidrosis.

Authors:  J W White
Journal:  Mayo Clin Proc       Date:  1986-12       Impact factor: 7.616

5.  [Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis].

Authors:  C Try; R Messikh; A Elkhyat; F Aubin; R P Humbert
Journal:  Rev Med Liege       Date:  2012-10

6.  [Evaluation of discomfort and complications in a population of 18,102 patients overweight or obese patients].

Authors:  J-M Lecerf; C Reitz; A de Chasteigner
Journal:  Presse Med       Date:  2003-04-26       Impact factor: 1.228

7.  Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers.

Authors:  K M Hughes; J C Lang; R Lazare; D Gordon; S L Stanton; J Malone-Lee; M Geraint
Journal:  Xenobiotica       Date:  1992-07       Impact factor: 1.908

8.  Long-term results of the use of oxybutynin for the treatment of axillary hyperhidrosis.

Authors:  Nelson Wolosker; Marcelo Passos Teivelis; Mariana Krutman; Rafael Pessanha de Paula; Paulo Kauffman; José Ribas M de Campos; Pedro Puech-Leão
Journal:  Ann Vasc Surg       Date:  2014-02-08       Impact factor: 1.466

Review 9.  Hyperhidrosis: a review of current management.

Authors:  Joanne L Atkins; Peter E M Butler
Journal:  Plast Reconstr Surg       Date:  2002-07       Impact factor: 4.730

10.  Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin.

Authors:  Marcelo Passos Teivelis; Nelson Wolosker; Mariana Krutman; Paulo Kauffman; José Ribas Milanez de Campos; Pedro Puech-Leão
Journal:  Clinics (Sao Paulo)       Date:  2014-09       Impact factor: 2.365

View more
  3 in total

1.  Methadone-Induced Hyperhidrosis Treated With Oxybutynin.

Authors:  Joe Hong; Jooyeon Lee; Holly Totouom-Tangho; Norma Ramos Dunn; Ronnie Gorman Swift
Journal:  J Addict Med       Date:  2017 May/Jun       Impact factor: 3.702

2.  Management Strategies Of Palmar Hyperhidrosis: Challenges And Solutions.

Authors:  Stamatios Gregoriou; Polytimi Sidiropoulou; Georgios Kontochristopoulos; Dimitrios Rigopoulos
Journal:  Clin Cosmet Investig Dermatol       Date:  2019-10-04

3.  Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review.

Authors:  Emanuela Martina; Federico Diotallevi; Giulia Radi; Anna Campanati; Annamaria Offidani
Journal:  Toxins (Basel)       Date:  2021-02-05       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.